# The Fat Pads in Your Ears

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-fat-pads-in-your-ears

> Your eustachian tube is held closed partly by fatty cushions. Two cases describe it staying open after weight loss on a GLP-1, and the adverse event database records the symptom zero times.

## Key points

- Two cases with endoscopy confirming loss of tissue bulk in the eustachian tube cushions.
- Autophony appears ZERO times in 97,237 adverse event reports for the class.
- Publishing both halves is what makes the paper useful rather than persuasive.
- But a zero in a spontaneous database is weak evidence of absence, because few would report this.
- Dulaglutide leads the tube-related count (417), which is not the ranking fat loss would predict.

Your eustachian tube is held closed partly by small fatty cushions. Lose enough fat and it can stay open, which makes your own voice and breathing boom inside your head. Two published cases describe exactly that after starting a GLP-1, with endoscopy confirming the cushions had thinned.[1] Then the authors searched the FDA’s adverse event database and found the symptom reported **zero times**.

## An elegant mechanism

The eustachian tube connects the middle ear to the back of the throat and equalizes pressure. It is normally shut, opening briefly when you swallow or yawn. Part of what keeps it shut is bulk in the surrounding tissue, including fat.

When that bulk is lost, the tube can become *patulous*, or stuck open. The result is autophony: your own voice, your breathing, sometimes your heartbeat, transmitted directly into the middle ear. People describe it as speaking into a barrel. It is not dangerous, but it is unpleasant, and it is a known consequence of rapid weight loss from any cause.

In the two cases reported here, nasal endoscopy confirmed significant loss of tissue bulk in the anterior and posterior cushions of the tube. This was seen directly, not inferred.

## The check that did not confirm it

> **Across 97,237 adverse events reported for GLP-1 drugs, autophony appears zero times.** Ear fullness appears twice. The specific symptom these cases are built around has never been reported to the FDA in connection with this drug class.

*Otologic adverse events in FAERS for GLP-1 receptor agonists: 958 of 97,237 total (0.99%).[1]*

| Event | Reports |
| --- | --- |
| Hypoacusis (reduced hearing) | 515 |
| Vertigo | 203 |
| Deafness | 97 |
| Tinnitus | 93 |
| Ear pain | 22 |
| Motion sickness | 21 |
| Hyperacusis | 5 |
| Ear fullness | 2 |
| **Autophony** | **0** |

Note also what dominates that list. More than half of all otologic reports are hypoacusis (reduced hearing), which is a different problem from a tube that will not close, and would not be produced by the mechanism described above. What the newer studies say about reduced hearing and tinnitus is in [GLP-1 tinnitus and hearing loss](https://glpwatchdog.org/research/glp1-tinnitus-and-hearing).

## Why publishing both halves is the right thing to do

> A beautiful mechanism plus two cases is a hypothesis. The database was the test.

It would have been easy to publish the cases and the anatomy and stop. The mechanism is coherent, the endoscopy is convincing, and nobody would have checked. Reporting the zero alongside them is what makes this a useful paper rather than a persuasive one.

> **But a zero in a spontaneous reporting database is weak evidence of absence, and this is a good example of why.** Reports only exist when someone connects a symptom to a drug and troubles to file. “My own voice sounds strangely loud” is not something most people would call their pharmacy about, and few would connect it to a weight-loss injection. The other limits of this database are set out in [the drugs nobody writes about](https://glpwatchdog.org/research/the-drugs-nobody-writes-about).

So the question is unresolved. A specific, visible, anatomically confirmed mechanism exists in two people. Whether it happens at any meaningful rate is not answerable from a database that would probably not capture it.

One further oddity, consistent with something we have found before: the largest count of potentially tube-related events belongs to **dulaglutide**, at 417, not to the drugs producing the most weight loss and attracting the most attention. If fat loss around the tube were driving this, that is not the ranking you would expect.

## What to do if this is happening to you

- **It is not dangerous**, and it is not imaginary. Patulous eustachian tube dysfunction is a recognized condition with a recognized cause.
- **How long it lasts is not established.** The cases describe tissue lost from the cushions, and neither they nor the database say how often it resolves.
- **An ear, nose and throat clinician can see it.** The endoscopy in these cases showed the tissue directly, so this is a symptom with an objective finding behind it.
- **Say what you take.** The connection is obscure enough that a clinician may not raise it, and rapid weight loss is the relevant history.

This is a minor problem in a field full of major ones. It appears here because a symptom with a mechanism and no reports is a good example of how to hold an uncertain finding, and because someone experiencing it is currently unlikely to find anything written about it at all.

## Frequently asked questions

### Can GLP-1 drugs cause ear symptoms?

Two published cases describe autophony (hearing your own voice and breathing loudly) after starting one, with endoscopy showing thinning of the fatty cushions that normally hold the eustachian tube closed. Whether this happens at any meaningful rate is unknown.

### What is autophony?

The sensation of your own voice, breathing or heartbeat sounding abnormally loud inside your head. It occurs when the eustachian tube stays open instead of closing, which is a recognized consequence of rapid weight loss from any cause.

### How common is it?

Unknown, and possibly very rare. Across 97,237 adverse event reports for this drug class, autophony appears zero times and ear fullness twice. That is weak evidence of absence, though, because few people would connect the symptom to a weight-loss injection or report it.

### What ear problems are actually reported?

Otologic events make up 0.99% of reports, and more than half (515 of 958) are reduced hearing, which is a different problem from a tube that will not close.

### Will it go away?

Nobody knows yet. The cases describe tissue lost from the cushions around the tube, and the paper does not report how often the symptom resolves. An ear, nose and throat clinician can examine the tube directly, and it is worth mentioning both the medication and the rate of weight loss.

## References

1. Pak KY, Cutri RM, Nadeem W, et al. GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events. Otology & Neurotology. 2025. PMID: 39666743. https://pubmed.ncbi.nlm.nih.gov/39666743/

---

Cite as: GLP Watchdog, Nora Bissett, "The Fat Pads in Your Ears", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-fat-pads-in-your-ears

Canonical HTML page: https://glpwatchdog.org/research/the-fat-pads-in-your-ears

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
